NASDAQ:MCRBSeres Therapeutics Stock Price, Forecast & News

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MCRB stock has increased by 77.3% and is now trading at $4.68. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seres Therapeutics.

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Seres Therapeutics.

Seres Therapeutics Inc (NASDAQ:MCRB) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.28). The biotechnology company earned $8.19 million during the quarter, compared to analysts' expectations of $8.01 million. View Seres Therapeutics' earnings history.

6 equities research analysts have issued 12-month target prices for Seres Therapeutics' shares. Their forecasts range from $4.00 to $11.00. On average, they expect Seres Therapeutics' share price to reach $7.50 in the next year. This suggests a possible upside of 60.3% from the stock's current price. View analysts' price targets for Seres Therapeutics.

News headlines about MCRB stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Seres Therapeutics earned a daily sentiment score of 0.7 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutSeres Therapeutics.

Seres Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,590,000 shares, an increase of 9.6% from the April 30th total of 5,100,000 shares. Based on an average daily trading volume, of 320,700 shares, the short-interest ratio is presently 17.4 days. Currently, 13.1% of the shares of the stock are short sold. View Seres Therapeutics' Current Options Chain.

Some companies that are related to Seres Therapeutics include Intra-Cellular Therapies (ITCI), Arvinas (ARVN), Karyopharm Therapeutics (KPTI), Tricida (TCDA), I-Mab (ARQT), Supernus Pharmaceuticals (SUPN), Phathom Pharmaceuticals (PHAT), Revance Therapeutics (RVNC), Kiniksa Pharmaceuticals (KNSA), Odonate Therapeutics (ODT), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), Cytokinetics (CYTK), Mersana Therapeutics (MRSN) and Phibro Animal Health (PAHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Exelixis (EXEL) and Gilead Sciences (GILD).

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Seres Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (11.83%), Nikko Asset Management Americas Inc. (11.83%), Sumitomo Mitsui Trust Holdings Inc. (11.83%), BlackRock Inc. (5.55%), JPMorgan Chase & Co. (1.44%) and Federated Hermes Inc. (1.42%). Company insiders that own Seres Therapeutics stock include Eric D Shaff, John G Aunins, Marcus Chapman, Noubar Afeyan, Roger Pomerantz and Thomas Desrosier. View institutional ownership trends for Seres Therapeutics.

MCRB stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, AXA, Two Sigma Investments LP, BlackRock Inc., Parametric Portfolio Associates LLC, Morgan Stanley, Jane Street Group LLC, and State Street Corp. View insider buying and selling activity for Seres Therapeutics.

MCRB stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., JPMorgan Chase & Co., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Geode Capital Management LLC, Alliancebernstein L.P., and Two Sigma Advisers LP. View insider buying and selling activity for Seres Therapeutics.

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MCRB stock can currently be purchased for approximately $4.68.

Seres Therapeutics has a market capitalization of $339.76 million and generates $34.51 million in revenue each year. The biotechnology company earns $-70,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe.

The official website for Seres Therapeutics is www.serestherapeutics.com.

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]